TENNESSEE RETINA

Real-World Study Confirms Safety and Efficacy of Aflibercept Biosimilar Pavblu in 6,313 Patients

- A large real-world study of 7,773 eyes from 6,313 patients treated with Pavblu (aflibercept-ayyh) showed stable vision outcomes with no unexpected safety concerns across 255 locations nationwide. - The biosimilar demonstrated comparable efficacy to reference aflibercept in a phase 3 trial of 579 patients with neovascular age-related macular degeneration, with 95.6% maintaining vision at week 52. - Only 0.01% of patients experienced serious eye infections (endophthalmitis) and 0.09% had minor inflammation, confirming the biosimilar's safety profile matches the reference product. - Pavblu secured national insurance coverage for approximately 80% of patients as of May 2025, potentially improving access to anti-VEGF therapy while reducing healthcare costs.